MA-IMMUTA
20.5.2021 15:02:06 CEST | Business Wire | Press release
Immuta , the leading provider of cloud data access control, today announced that it has secured $90 million in Series D funding. Immuta will use the investment to further its market leadership position and capture rising demand for centralized, scalable access control across cloud data sets that are increasingly diverse and distributed on multiple compute platforms. The new investment comes less than a year after Immuta’s Series C investment and brings total capital raised to $169 million.
The Series D funding round includes new investors Greenspring Associates, March Capital, NGP Capital, and Wipro Ventures, as well as participation from existing investors Ten Eleven Ventures, Intel Capital, DFJ Growth, Dell Technologies Capital, Citi Ventures, and Okta Ventures. The investment will go towards accelerating Immuta’s product research and development, expanding sales and marketing capacity to capture growing demand in the U.S., EMEA, and APAC, and deepening strategic partnerships within the cloud data ecosystem. Amazon Redshift and Azure Synapse are the latest cloud data platforms to be integrated with Immuta’s platform as part of its latest release announced today .
“We’ve entered a new era in data and analytics fueled by ubiquitous cloud storage, new cloud data management tools, and the rise of DataOps,” said Immuta’s CEO Matthew Carroll. “In this new environment, data teams are challenged to provide secure, scaled access to thousands of cloud data products while maintaining strong security, privacy protection, and auditability. Traditional methods of data access control don’t work, don’t scale across cloud compute platforms, and can limit data utility. Immuta’s platform solves this problem elegantly without requiring data to be moved, copied, or manually provisioned. This new funding will accelerate innovation and GTM expansion so we can deliver our platform to more customers as we lead the charge to define the future of cloud data access control.”
“We looked at other competition in the space and Immuta’s product and solutions are really at the top of the heap,” said Hunter Somerville, General Partner at Greenspring Associates. “ From intelligent data discovery, to data access and control, to integration with all the top cloud analytics services, Immuta’s platform is best-in-class. We also liked that Immuta prioritized the data architecture and engineering team, from an end-sales standpoint, which we didn't see from other solutions in the space.”
“We invest in tomorrow’s winners,” said Jed Leidheiser, Partner at March Capital. “I look for companies that have tremendous customer satisfaction today, with architectures built for platform expansion, and an A+ team to execute. That’s Immuta. They have the ability to operate on any data source, any infrastructure, any cloud platform — and on top of that, their customer list is rapidly growing.”
Since its founding in 2015, Immuta has built strategic partnerships with the leading cloud data technology providers and enhanced its platform to provide a single place for data teams to automate data across control across their entire cloud infrastructure. As the market leader, Immuta helps large enterprises scale centralized data operations and analytics teams and helps innovative technology companies build and scale data-powered apps and services. In its last fiscal year, Immuta grew worldwide bookings by more than 115%, doubled its full-time headcount, and expanded its global base of customers including Aon, Credit Suisse, Daimler, Flatiron, IAG, S&P Global, and US Army.
"Immuta has been a longtime partner of Databricks and we are excited to see this impressive round of funding. We look forward to helping bring their cloud data access control capabilities to more joint customers as they're building their future data and analytics stack on the lakehouse platform," said Ali Ghodsi, CEO and co-founder of Databricks.
“One of the really big advantages that Immuta has given us, from a return-on-investment perspective, is our ability to make change happen faster,” said Dave Abrahams, Executive
General Manager of Data, IAG, one of Australia and New Zealand’s largest general insurance providers and an Immuta investor. “Previously, it would take months of manual assessments, and working through the challenges around how we could access and use data to help create the best products for our customers. We are now able to do that in an instant, globally, across all of our data.”
For more information about Immuta, visit www.immuta.com . Join the Immuta conversation on LinkedIn and Twitter .
About Immuta
Immuta is the market leader in cloud data access control, providing data engineering and operations teams one universal platform to control access to analytical data sets in the cloud. Only Immuta can automate access control for any data, on any cloud service, across all compute infrastructure. Data-driven organizations around the world rely on Immuta to speed time to data, safely share more data with more users, and mitigate the risk of data leaks and breaches. Founded in 2015, Immuta is headquartered in Boston, MA. Learn more at www.immuta.com .
About Greenspring
Greenspring Associates was founded in 2000 to focus solely on venture capital investments. Through a comprehensive platform, the Firm serves as a lifecycle partner for fund managers and entrepreneurs, investing across multiple stages, sectors and geographies. Greenspring Associates currently manages over $12 billion in committed capital across a variety of specialized venture strategies on behalf of a diverse group of global investors. For more information on Greenspring Associates, please visit its website at www.greenspringassociates.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release
Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea
Beyond the ‘Dumb Pipe’: How Agentic AI and Sovereign Networks Are Redefining Connectivity23.6.2026 14:46:00 CEST | Press release
The global connectivity market is shifting. With traditional European telecom growth slowing to 2-3% by 2029, businesses must adapt through Agentic AI, critical communications, and digital sovereignty. To remain competitive, operators should move beyond infrastructure toward an API-driven economy. These trends took center stage at Comarch User Group 2026. The conference hosted over 700 partners from 53 countries, including 201 connectivity experts, highlighting how companies can thrive in regulated environments. As telecom growth slows, demand for broader connectivity solutions across satellite, logistics, and critical communications is surging. Operators must abandon the old 4G “dumb pipe” model, where they act merely as network providers charging only for raw data transmission, for an API-driven economy with programmable network quality, securely integrating 5G with new satellite and IoT ecosystems. - Marcin Kaleta, CEO at Comarch Communications Putting Agentic AI in the Driver's Sea
Mary Kay Extends Winning Streak With Fourth Year as #1 in Global Direct Selling Beauty23.6.2026 14:03:00 CEST | Press release
Euromonitor International Recognizes Mary Kay’s Sustained Leadership In Skin Care And Color Cosmetics Mary Kay Inc., the iconic beauty and entrepreneurship company, has once again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International, sustaining its legacy of excellence for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623487381/en/ Mary Kay Inc., the iconic beauty and entrepreneurship company, for the fourth year in a row has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International. (Image Credit: Mary Kay Inc.) “Earning the #1 global ranking from Euromonitor for the fourth consecutive year comes as a powerful endorsement of the impact of our Independent Beauty Consultants around the world who drive our success every day,” said Ryan Rogers, Chief Executive Officer of Mary Kay
Kobie 2026 Heart of Loyalty Report Reveals Growing Gap Between Consumer Expectations and Brand Loyalty Strategies23.6.2026 14:00:00 CEST | Press release
Global study finds consumers are more ready for AI, more willing to share data, and more motivated by recognition and shared values than many brands realize Kobie, a global leader in loyalty technology and services, today released its 2026 Heart of Loyalty Report, which surveyed both consumers and practitioners, revealing significant gaps between consumer expectations and brand loyalty strategies across AI adoption, data sharing, recognition, advocacy, and community engagement. Kobie's 2026 Heart of Loyalty Report found that: 57% of consumers are willing to engage with AI-powered brand experiences, yet 56% of loyalty practitioners believe customers are not ready for AI. 77% of consumers want recognition from brands, but only 55% feel seen as individuals. 72% of consumers say they would refer a brand without an incentive, yet many referral strategies remain heavily dependent on rewards. Rewards are the strongest driver of willingness to share personal data, yet only 65% of practitioners
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release
Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
